HELSINKI, Dec 12 (Reuters) - The European Medicines Agency (EMA) will allow Novo Nordisk (NOVOb.CO), opens new tab to add risk reduction for events related to kidney disease to the label of its ...

label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction from Ozempic therapy in chronic kidney disease-related events. Also Read: Want To Bet On ...

Bogg Bag’s viral popularity isn’t slowing down just yet. The functional accessories brand founded by chief executive officer Kim Vaccarella is expanding into Target on Sunday, marking its ...

HELSINKI (Reuters) - The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish ...

Kidney function tests are simple procedures that use either blood or urine to help identify kidney problems. There are a few types of kidney function tests, which investigate various aspects of ...

The label update is based on a trial where Novo demonstrated that the use of semaglutide reduced the risk of kidney disease progression, Novo added. The company Story by Reuters ...

Omega-3 fats may help reduce fat levels (triglycerides) in the blood and may also lower blood pressure, according to the National Kidney Foundation. If you have CKD, you may need to keep an eye ...

Kidney disease affects approximately 850 million people globally. This incidence is predicted to rise with the increased prevalence of risk factors such as ...